255 related articles for article (PubMed ID: 20932241)
1. Inhalational therapy for pulmonary arterial hypertension: current status and future prospects.
Gupta V; Ahsan F
Crit Rev Ther Drug Carrier Syst; 2010; 27(4):313-70. PubMed ID: 20932241
[TBL] [Abstract][Full Text] [Related]
2. Iloprost inhalation solution for the treatment of pulmonary arterial hypertension.
Hsu HH; Rubin LJ
Expert Opin Pharmacother; 2005 Sep; 6(11):1921-30. PubMed ID: 16144511
[TBL] [Abstract][Full Text] [Related]
3. Prostacyclin therapy for pulmonary arterial hypertension: new directions.
Gomberg-Maitland M; Preston IR
Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of prostacyclin and its analogs in the management of pulmonary arterial hypertension.
Dandel M; Hetzer R
Curr Vasc Pharmacol; 2003 Jun; 1(2):171-81. PubMed ID: 15320842
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
6. Prostanoid therapy for pulmonary arterial hypertension.
Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
[TBL] [Abstract][Full Text] [Related]
7. Inhalation of repurposed drugs to treat pulmonary hypertension.
Gessler T
Adv Drug Deliv Rev; 2018 Aug; 133():34-44. PubMed ID: 29886070
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.
Opitz CF; Wensel R; Bettmann M; Schaffarczyk R; Linscheid M; Hetzer R; Ewert R
Eur Heart J; 2003 Feb; 24(4):356-65. PubMed ID: 12581683
[TBL] [Abstract][Full Text] [Related]
9. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
Gessler T; Seeger W; Schmehl T
Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
[TBL] [Abstract][Full Text] [Related]
10. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
[TBL] [Abstract][Full Text] [Related]
11. Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension.
Gildea TR; Arroliga AC; Minai OA
Cleve Clin J Med; 2003 Apr; 70 Suppl 1():S18-27. PubMed ID: 12716139
[TBL] [Abstract][Full Text] [Related]
12. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension].
Osvaldo Cáneva J; Ossés JM
Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911
[TBL] [Abstract][Full Text] [Related]
13. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
14. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based pharmacologic management of pulmonary arterial hypertension.
Benedict N; Seybert A; Mathier MA
Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
[TBL] [Abstract][Full Text] [Related]
16. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
Beghetti M
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of pulmonary hypertension with aerosolized iloprost.
Machherndl S; Kneussl M; Baumgartner H; Schneider B; Petkov V; Schenk P; Lang IM
Eur Respir J; 2001 Jan; 17(1):8-13. PubMed ID: 11307761
[TBL] [Abstract][Full Text] [Related]
18. Treprostinil for the treatment of pulmonary arterial hypertension.
Torres F; Rubin LJ
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
[TBL] [Abstract][Full Text] [Related]
19. Role of iloprost and bosentan in pulmonary arterial hypertension.
Saleh JA
Niger J Med; 2008; 17(1):13-9. PubMed ID: 18390125
[TBL] [Abstract][Full Text] [Related]
20. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.
Budev MM; Minai OA; Arroliga AC
Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
